A critical evaluation of the therapeutic range of indinavir

OBJECTIVE: To provide a summary of the patient population, study characteristics, and important findings of the key studies in the literature evaluating concentration-effect relationships and the therapeutic range for indinavir. DATA SOURCES: Literature search strategy involved using MEDLINE (1966-July 2001) and AIDSLINE (MEDSCAPE) databases (up to July 2001). Reference lists from primary literature and review articles were also examined, and conference abstracts were obtained. STUDY SELECTION: English-language articles were considered suitable for review if the clinical trials in HIV patients reported on concentration-effect relationships and/or pharmacokinetic breakpoints or threshold concentrations. A search of the literature identified 20 peer-reviewed references from 18 separate studies including journal articles and conference abstracts. DATA EXTRACTION: The targeted pharmacokinetic parameters and breakpoint values, the rationale for their selection or method of identification, and other study details and limitations were summarized. DISCUSSION: This article highlights the heterogeneity of studies evaluating the therapeutic range of indinavir and provides a summary of important findings of the key studies in the literature evaluating concentration-effect relationships and therapeutic range. Tables are provided to enable clinicians to make use of currently available information on the therapeutic range of indinavir. CONCLUSIONS: There is insufficient evidence to recommend a general therapeutic range for indinavir. Future investigations should incorporate both pharmacokinetics and pharmacodynamics in order to define a broadly applicable therapeutic range.

This article has been cited by other articles:

				F. S. Rhame, S. L. Rawlins, R. A. Petruschke, T. A. Erb, G. A. Winchell, H. M. Wilson, J. M. Edelman, and M. A. Abramson Pharmacokinetics of Indinavir and Ritonavir Administered at 667 and 100 Milligrams, Respectively, Every 12 Hours Compared with Indinavir Administered at 800 Milligrams Every 8 Hours in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4200 - 4208. [Abstract] [Full Text] [PDF]

				C. Csajka, C. Marzolini, K. Fattinger, L. A. Decosterd, A. Telenti, J. Biollaz, and T. Buclin Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3226 - 3232. [Abstract] [Full Text] [PDF]